Abbott announced that the U.S. FDA has approved the company’s first-of-its-kind TriClip transcatheter edge-to-edge repair system that’s specifically designed for the treatment of tricuspid regurgitation, or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstention that the benefits of TriClip outweighed the risks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Court rules DexCom infringed one of three Abbott patents, Bloomberg Law reports
- FDA reports Abbott recalls HeartMate Touch Communication System
- Abbott announces new data from studies with GLP-1 medicines and Freestyle Libre
- Abbott Declares 401st Consecutive Quarterly Dividend
- Abbott announces FDA voted in favor of its TriClip System
